Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BST-104 in Mild to Moderate Functional Dyspepsia
NCT04008901Phase 3Completed
- Sponsor
- Seoul National University Bundang Hospital
- Start
- Feb 2017
- Primary completion
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of BST-104 in functional dyspepsia (FD) (2 arms), sponsored by Seoul National University Bundang Hospital. Primary endpoint: Gastrointestinal Symptom Rating Scale total score improvement at 8 weeks. Started Feb 2017; status: completed.
02
Drugs
BST-104
03
Conditions
functional dyspepsia (FD)
Beyond the preview
Go deeper on NCT04008901.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04008901.